Genmab — December 2019
-
The DuoBody MIM-8 (Novo Nordisk) will start phase 1/2 early next year. At the Novo Capital Markets Day held 20th Nov it is stated that they have an approved IND and "will start phase 1/2 trials that can be made adaptive so hopefulle fast can move into pivotal trials". Ref slide 12 in the presentation and approx 20 mins into the webcast
-
-
Såfremt Darzalex når 3mia USD i salg i pr og Genmab så fremadrettet får 20% af salget mon ikke det så resulteret i forhøjede kursmål 1750-2000
-
Impact of Daratumumab Monotherapy on Bone Parameters in Relapsed Refractory Multiple Myeloma Pts - https://www.youtube.com/watch?v=LxVzZtY-Hf8
-
Danske Bank hæver target til 1750 fra 1650
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind